ulocytes, monocytes, and blasts in MDS and non-clonal disorders by using routine FCM. Moreover, we evaluated the phenotypic abnormalities of mature cells in leukemic patients, which have never been evaluated. 
MATERIALS AND METHODS

Subjects
Characteristics of subjects with non-clonal disorders, MDS, and leukemia
The clinical characteristics and laboratory findings of patients at the time of initial diagnosis are shown in Table   1 . The patients in the MDS group were significantly older than the patients with non-clonal disorders. The leukocyte count was higher and there were fewer mature granulocytic cells in the leukemic patients compared to the patients with non-clonal disorders and MDS. Both the MDS and leukemia groups had lower hemoglobin levels than the patients with non-clonal disorders. Cytogenetic abnormalities were more frequent in the MDS and leukemia group compared to the non-clonal disorders group. There were no other statistically significant comparisons.
Immunophenotyping
Samples were analyzed using 3-color combinations of FITC, PE, and PC5-conjugated monoclonal antibodies (Becton Coulter, Fullerton, CA, USA) for CD13, CD33, CD3, CD7, CD5, CD56, CD19, CD20, CD22, CD10, CD34, HLA-DR, and CD45 by using Cytomics FC500 and CXP software (Beckman Coulter). The routine panel for the characterization of acute leukemia used in our study is shown in Table 2 .
Blasts, non-blast myeloid cells, and monocytes were gated based on CD45 expression and side scatter (SSC) (Fig. 1 ).
Back-gating was also used to identify or confirm cells of interest by using CD34 for blasts and CD14 for monocytes.
When the gated cells were uncertain or very small to count, the data were excluded. Mean fluorescence intensity (MFI) on the EGIL criteria [9] . In cases of CD10 in granulocytes and CD19 in the blast gate, which were expected to be positive only in the subpopulation of gated cells, positivity was defined as the presence of a positive subpopulation [6] .
Conventional cytogenetics
We performed conventional cytogenetic analysis on heparinized whole bone marrow samples by using standard protocols and analyzed the samples following Giemsa banding. Twenty metaphases were evaluated for each sample.
Statistics
Relationships between variables were analyzed using the 
RESULTS
Immunophenotypic features of granulocytic lineages
The immunophenotypic features of granulocytic lineages are listed in Table 3 (Table 4) . Table 5 shows the immunophenotypic features of monocytic lineages. The fluorescence intensities of CD13 and CD33 in the monocyte lineages were much higher than the
Immunophenotypic features of monocytic lineages
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Abbreviations: FITC, fluorescein isothiocyanate; PE, phycoerythrin; PC5, phycoerythrin-cyanin 5.   FITC  PE  PC5   CD10  CD19  CD45  CD20  CD5  CD45  CD3  CD22  CD45  CD7  CD33  CD45  HLA-DR  CD13  CD45  CD14  CD34  CD45  CD56 CD45 Table 2 . Combinations of monoclonal antibodies 
Immunophenotypic features of blast gating
The immunophenotypic features of blast gating are shown in A decreased SSC in MDS has been reported in prior studies [4, 5, 19, 21] , suggesting that this is a consistent finding in MDS. Hypogranularity in mature granulocytes is also a well-known morphologic feature of MDS. The degree of decreased SSC in MDS as compared to non-clonal disorders was more evident in the mature granulocytes than in the immature blasts. However, a previous study reported that decreased SSC was more evident in the immature stages of MDS [19] . Aberrant expression is one of the important changes in MDS, and CD56 was frequently expressed in the granulocytes of MDS patients, whereas CD56 was only found in one of the patients in the non-clonal disorders group (Table 3) . This patient had pancytopenia, with no evidence of hematologic malignancy on bone marrow examination, although a follow-up study was warranted.
Aberrant expression of CD56 was previously reported in myeloblasts [22, 23] and mature granulocytes in MDS [4, Data are median (range), except positive rate (positive case/total cases with available data). Statistical significance analysis was performed for comparison of non-clonal disorders vs other groups and MDS vs leukemia. *P<0.05 compared to non-clonal disorders;
.05 compared to MDS. Abbreviations: See Table 3 . [5] . CD56 expression is not a specific finding
and might be present in cells following the administration of growth factors or chemotherapy [25] . However, this finding is useful in the naive bone marrow without a history of growth factor or chemotherapy administration because the frequency of CD56 expression is high in MDS and very rare in non-clonal disorders. In our study, the higher frequency of CD56 expression in MDS compared to non-clonal disorders was more prominent in non-blast granulocytes (P=0.005) than in immature blasts (P=0.020).
Decreased CD10 expression in the neutrophils of patients with MDS has been previously reported [4, 11, 24] , and this finding was also evident in our study. In non-clonal disorders, CD10-positive cells in granulocyte gating were found in one-third of the patients. Most of these patients had hypocellular marrow with a relative predominance of neutrophils, and the amount CD10-positive cells ranged from 8.7% to 50.1% with low intensities (MFI 1.2-2.0). In contrast, the CD10-positive population was rarely noted in patients with MDS. CD10/neutral endopeptidase plays an important role in the control of chemotaxis and the inflammatory response of neutrophils [11, 26] , and the reduction of CD10-positive granulocytes has been suggested to contribute to infection susceptibility [11] .
The immunophenotypic changes observed in patients with MDS were also noted in leukemic patients. Abnormalities such as decreased SSC, decreased CD10-positive granulocytes, and aberrant expression were also present in non-blast granulocytes in leukemia patients. These changes were unlikely to be related to the leukemic cells.
Among 6 patients with CD56-positive non-blast granulocytes, 3 patients showed no CD56 expression in leukemic blasts, while the other 3 had CD56-positive leukemic blasts.
However, other antigens expressed in CD56-positive leukemic cells, such as CD7 and HLA-DR, were not expressed in the non-blast granulocytes (Table 4) . Moreover, the intensity of CD56 was different between leukemic cells and non-blast granulocytes (data not shown). Thus, these features of non-blast granulocytes in leukemic patients were suspected not to be clonal changes related to leukemia but rather, reactive changes or changes due to immaturity.
MDS is a clonal disorder of myeloid cells from the immature to the mature stages. It is unclear whether the immunophenotypic changes of granulocytes in our study were clonal or non-clonal. We found that the phenotypic changes identified in MDS were also seen in leukemia. Nevertheless, immunophenotyping may be useful in distinguishing MDS from non-clonal disorders because the changes were rarely observed in the non-clonal disorders, and this is especially true in cases with uncertain morphologic features. Using blast and monocytic gating, useful parameters for creating a differential diagnosis were not identified. The aberrant expression of CD56 and CD5 was only noted in a few patients. Moreover, these cell populations were occasionally obscured in the routine gating, especially when the sample was from a hypocellular marrow. Additional parameters and back-gating were often required for clarification.
In conclusion, granulocyte gating is the most useful FCM tool for immunophenotyping MDS because it is easy to gate, and the results are easy to interpret. Among the parameters studied, SSC, CD10, and CD56 were the most useful for differentiating MDS from non-clonal disorders. Immunophenotypic changes in MDS may be useful for differentiating MDS from non-clonal disorders, although these changes were also noted in the mature cells of patients with leukemia.
